A detailed history of Allworth Financial LP transactions in Exelixis, Inc. stock. As of the latest transaction made, Allworth Financial LP holds 378 shares of EXEL stock, worth $13,048. This represents 0.0% of its overall portfolio holdings.

Number of Shares
378
Previous 586 35.49%
Holding current value
$13,048
Previous $13,000 30.77%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

SELL
$21.96 - $27.6 $4,567 - $5,740
-208 Reduced 35.49%
378 $9,000
Q2 2024

Jul 23, 2024

BUY
$20.34 - $23.73 $3,132 - $3,654
154 Added 35.65%
586 $13,000
Q1 2024

Apr 25, 2024

BUY
$20.17 - $23.93 $242 - $287
12 Added 2.86%
432 $10,000
Q4 2023

Jan 24, 2024

BUY
$19.25 - $24.13 $2,136 - $2,678
111 Added 35.92%
420 $10,000
Q3 2023

Oct 31, 2023

BUY
$19.04 - $22.74 $1,066 - $1,273
56 Added 22.13%
309 $6,000
Q2 2023

Jul 18, 2023

SELL
$18.17 - $20.48 $19,787 - $22,302
-1,089 Reduced 81.15%
253 $4,000
Q1 2023

Apr 18, 2023

BUY
$16.3 - $19.41 $16,707 - $19,895
1,025 Added 323.34%
1,342 $26,000
Q4 2022

Jan 13, 2023

SELL
$14.96 - $17.39 $553 - $643
-37 Reduced 10.45%
317 $0
Q3 2022

Oct 18, 2022

BUY
$15.68 - $22.27 $1,928 - $2,739
123 Added 53.25%
354 $6,000
Q2 2022

Jul 13, 2022

SELL
$17.44 - $23.16 $8,807 - $11,695
-505 Reduced 68.61%
231 $5,000
Q1 2022

Apr 22, 2022

BUY
$17.03 - $22.67 $3,406 - $4,534
200 Added 37.31%
736 $17,000
Q4 2021

Jan 21, 2022

BUY
$15.84 - $21.88 $8,173 - $11,290
516 Added 2580.0%
536 $10,000
Q2 2017

Aug 07, 2017

BUY
N/A
20
20 $0

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.1B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Allworth Financial LP Portfolio

Follow Allworth Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allworth Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Allworth Financial LP with notifications on news.